Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic

Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first enrollment site, Dedicated to Women OB/GYN in Dover, Delaware, has already begun recruiting participants for this significant clinical validation effort.

Pearsanta President Chris Mitton emphasized the importance of this milestone, noting that it supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis. This development represents a potential breakthrough in women's healthcare, as current diagnostic methods typically require invasive surgical procedures that can delay diagnosis and treatment. The blood-based approach being studied could significantly reduce the time between symptom onset and definitive diagnosis, potentially improving patient outcomes and quality of life.

Aditxt operates as a social innovation platform advancing health innovations across multiple therapeutic areas. The company's current programs focus on autoimmunity, cancer and early disease detection, infectious diseases, and women's health. The endometriosis test development falls within the women's health program, addressing a significant unmet medical need in gynecological care. Additional information about Aditxt's initiatives and corporate updates can be found in the company's newsroom at https://ibn.fm/ADTX.

The clinical study's design involving comparison to the gold standard laparoscopic diagnosis provides rigorous validation parameters that could support regulatory approval and clinical adoption if successful. Endometriosis affects approximately 10% of women of reproductive age worldwide, with many experiencing diagnostic delays of 7-10 years from symptom onset. A reliable blood-based test could transform the diagnostic pathway, reducing healthcare costs and improving access to timely treatment.

The broader implications of this research extend beyond endometriosis diagnosis alone. Successful development of blood-based diagnostics for gynecological conditions could pave the way for similar approaches in other women's health areas, potentially revolutionizing how reproductive health conditions are screened and monitored. The study's progress and eventual outcomes will be closely watched by healthcare providers, patients, and the medical research community seeking less invasive diagnostic options for chronic conditions affecting women's health.